Call (844) 879-2237

Request additional information regarding Cerafix®

A Material Development Company

A bioscience company commercializing a portfolio of fully synthetic electrospun scaffolds for regenerative medical applications

Feature image

The FDA cleared Acera’s first product in March 2016 and its second product in April 2017, both via 510(k). Acera is currently raising Series A financing, as well as seeking strategic partners for product development and commercialization.

Feature image
Cytrell™

The Theme had a simple layout which attracts the Client to the Website. Also, the professional and Clean design .

Feature image
Acera Meshes
Biologic Properties

The Theme had a simple layout which attracts the Client to the Website. Also, the professional and Clean design .

Feature image
Acera Performance
Investment Opportunities

The Theme had a simple layout which attracts the Client to the Website. Also, the professional and Clean design .

Acera News

Dwayne Montgomery Joins Acera Surgical’s Board of Directors

St. Louis, MO—June 9, 2017— Acera Surgical Inc., a pioneer in regenerative medicine that utilizes its proprietary nanotechnology platform to create products for the major tissue defect markets, today announced that Dwayne Montgomery has joined Acera’s Board of Directors.  Mr. […]

Read More

Acera Surgical’s advanced wound care product, the Restrata™ Wound Matrix, gains FDA Approval

Acera Surgical Inc., (“Acera”) a bioscience company located in St. Louis, MO received 510(k) clearance from the Food and Drug Administration (FDA) for its innovative wound care product, the Restrata™ Wound Matrix on April 26th. Restrata™ is a fully-synthetic electrospun wound […]

Read More